JP2011527560A5 - - Google Patents

Download PDF

Info

Publication number
JP2011527560A5
JP2011527560A5 JP2010544332A JP2010544332A JP2011527560A5 JP 2011527560 A5 JP2011527560 A5 JP 2011527560A5 JP 2010544332 A JP2010544332 A JP 2010544332A JP 2010544332 A JP2010544332 A JP 2010544332A JP 2011527560 A5 JP2011527560 A5 JP 2011527560A5
Authority
JP
Japan
Prior art keywords
exemplify
cytokines
limited
type
further examples
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010544332A
Other languages
English (en)
Japanese (ja)
Other versions
JP5542064B2 (ja
JP2011527560A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/000424 external-priority patent/WO2009094172A2/en
Publication of JP2011527560A publication Critical patent/JP2011527560A/ja
Publication of JP2011527560A5 publication Critical patent/JP2011527560A5/ja
Application granted granted Critical
Publication of JP5542064B2 publication Critical patent/JP5542064B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010544332A 2008-01-22 2009-01-22 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体 Expired - Fee Related JP5542064B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US6201208P 2008-01-22 2008-01-22
US6204508P 2008-01-22 2008-01-22
US6202208P 2008-01-22 2008-01-22
US61/062,022 2008-01-22
US61/062,012 2008-01-22
US61/062,045 2008-01-22
US13391208P 2008-07-03 2008-07-03
US61/133,912 2008-07-03
US20389008P 2008-12-30 2008-12-30
US61/203,890 2008-12-30
PCT/US2009/000424 WO2009094172A2 (en) 2008-01-22 2009-01-22 Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014094974A Division JP6309815B2 (ja) 2008-01-22 2014-05-02 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体

Publications (3)

Publication Number Publication Date
JP2011527560A JP2011527560A (ja) 2011-11-04
JP2011527560A5 true JP2011527560A5 (enExample) 2012-03-15
JP5542064B2 JP5542064B2 (ja) 2014-07-09

Family

ID=40810017

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2010544332A Expired - Fee Related JP5542064B2 (ja) 2008-01-22 2009-01-22 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体
JP2014094974A Expired - Fee Related JP6309815B2 (ja) 2008-01-22 2014-05-02 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体
JP2016114592A Pending JP2017002040A (ja) 2008-01-22 2016-06-08 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体
JP2019031123A Pending JP2019123715A (ja) 2008-01-22 2019-02-25 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体
JP2021016186A Pending JP2021073281A (ja) 2008-01-22 2021-02-04 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2014094974A Expired - Fee Related JP6309815B2 (ja) 2008-01-22 2014-05-02 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体
JP2016114592A Pending JP2017002040A (ja) 2008-01-22 2016-06-08 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体
JP2019031123A Pending JP2019123715A (ja) 2008-01-22 2019-02-25 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体
JP2021016186A Pending JP2021073281A (ja) 2008-01-22 2021-02-04 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体

Country Status (15)

Country Link
US (4) US8853358B2 (enExample)
EP (2) EP2933264A3 (enExample)
JP (5) JP5542064B2 (enExample)
KR (7) KR20180041269A (enExample)
CN (4) CN102066413B (enExample)
AU (1) AU2009206748B2 (enExample)
CA (1) CA2712757A1 (enExample)
ES (1) ES2539124T3 (enExample)
HK (1) HK1215713A1 (enExample)
IL (1) IL207155A (enExample)
MX (3) MX356129B (enExample)
NZ (3) NZ621196A (enExample)
PL (1) PL2245056T4 (enExample)
SG (3) SG10201604530SA (enExample)
WO (1) WO2009094172A2 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9585932B2 (en) 2005-04-29 2017-03-07 Peter C. Dowling Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
US9345745B2 (en) * 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
WO2007052154A2 (en) 2005-04-29 2007-05-10 University Of Medicine And Dentistry Of New Jersey Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
EP1924276A4 (en) 2005-08-05 2009-07-22 Araim Pharmaceuticals Inc Antiperspirant peptides and their uses
WO2009094172A2 (en) 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
ES2773017T3 (es) 2010-04-06 2020-07-09 Synedgen Inc Derivados de quitosano para el tratamiento de mucositis o ulceración
US9999702B2 (en) * 2010-04-09 2018-06-19 Kci Licensing Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
WO2012069474A2 (en) 2010-11-24 2012-05-31 H. Lundbeck A/S A method for reducing potential virus burden in a sample by cyanate treatment
WO2012084895A2 (en) * 2010-12-20 2012-06-28 Universiteit Gent Crystal structure of flt3 ligand-receptor complex
WO2012174028A2 (en) * 2011-06-13 2012-12-20 The Board Of Trustees Of The University Of Illinois Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion
FR2978964B1 (fr) * 2011-08-09 2015-02-20 Conservatoire Nat Arts Composition vaccinale anti-il-6
CN105012313B (zh) * 2014-04-25 2018-03-16 广州市赛普特医药科技股份有限公司 5α‑雄甾‑3β,5,6β‑三醇及其类似物在预防或治疗低压缺氧引起的高原病中的应用
KR20140103122A (ko) * 2011-11-17 2014-08-25 넨키 인스티튜트 오브 익스페리멘탈 바이올로지 신경교종을 치료하기 위한 조성물 및 방법
US10022393B2 (en) * 2012-09-20 2018-07-17 Synedgen, Inc. Methods for treatment or prevention of damage resulting from radiation, trauma or shock
WO2014121063A1 (en) * 2013-01-31 2014-08-07 The Trustees Of The University Of Pennsylvania Repair of peripheral nerve injury
WO2014144095A2 (en) * 2013-03-15 2014-09-18 The Board Of Regents Of The University Of Oklahoma Compositions comprising d-amino acid peptides and methods of production and use thereof for inhibiting autoantibodies
CN105517561A (zh) * 2013-07-17 2016-04-20 阿拉伊姆药品公司 预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物
KR101510743B1 (ko) 2013-07-23 2015-04-10 (주)케어젠 파골 세포 분화 억제용 펩타이드 및 이의 용도
WO2015120458A1 (en) 2014-02-10 2015-08-13 Fred Hutchinson Cancer Research Center Halogen treatment of heart attack and ischemic injury
US9314457B2 (en) 2014-06-19 2016-04-19 The University Of Utah Research Foundation Methods of treating and preventing vascular instability diseases
GB2539161A (en) * 2014-11-26 2016-12-14 Neuro-Bio Ltd Neurodegenerative disorders
US12599670B2 (en) 2014-12-12 2026-04-14 The Trustees Of The University Of Pennsylvania Composition comprising three-dimensional astrocyte bundles of bi-polar and aligned astrocyte processes and a method of making thereof
WO2016172693A1 (en) * 2015-04-23 2016-10-27 Rowan University Novel slice cultures and methods for diagnosing neuronal degeneration diseases
CN105233256A (zh) * 2015-10-28 2016-01-13 中国人民解放军第三军医大学 促红细胞生成素及其衍生物在制备治疗疾病中促进凋亡细胞清除的药物中的应用
RU2613308C1 (ru) * 2015-11-23 2017-03-15 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования предрасположенности к послеоперационному кровотечению при раке головки поджелудочной железы
EP3442409A4 (en) 2016-04-14 2019-11-13 The Trustees of The University of Pennsylvania IMPLANTABLE LIVING ELECTRODES AND METHOD FOR USE THEREOF
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
JP2019523633A (ja) * 2016-04-29 2019-08-29 アライム ファーマシューティカルズ,インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド
CN106075392B (zh) * 2016-07-18 2020-07-07 滨州医学院 促红细胞生成素衍生物在听力保护上的应用
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Polypeptides derived from CSF-m and their uses
JP7123932B2 (ja) * 2016-09-02 2022-08-23 クリストファー ジェイ. ソアレス 神経保護及び神経疾患におけるcgrp受容体アンタゴニストの使用
ES2952448T3 (es) * 2016-11-10 2023-10-31 Asc Regenity Ltd Formulaciones cosméticas para aplicaciones tópicas que contienen moléculas derivadas de eritropoyetina
CN110475786A (zh) * 2017-02-27 2019-11-19 大邱庆北科学技术院 红细胞生成素衍生肽通过其对预防细胞损伤的作用的用途
JP6450999B2 (ja) * 2017-03-31 2019-01-16 国立大学法人群馬大学 B型ボツリヌス毒素を用いたレイノー現象の治療
US11479591B2 (en) * 2017-05-05 2022-10-25 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
CN110590919B (zh) * 2017-05-24 2022-05-24 中国海洋大学 含鸟氨酸的短肽及其应用
AU2018321825A1 (en) * 2017-08-19 2020-03-05 Ohio State Innovation Foundation Novel peptide-based cancer imaging agents
US20200223894A1 (en) * 2017-09-19 2020-07-16 Auckland Uniservices Limited Peptides for the treatment of conditions associated with adiponectin dysfunction
CN107880109B (zh) * 2017-11-01 2019-08-30 复旦大学附属中山医院 一种促红细胞生成素来源肽及其制备方法和用途
US10975124B2 (en) 2018-02-23 2021-04-13 The Board Of Regents Of The University Of Oklahoma Methods and compositions for treating diseases and conditions associated with gonadotropin releasing hormone receptor
KR102167641B1 (ko) 2018-08-27 2020-10-19 주식회사 사이루스 에리스로포이에틴 유래 펩티드를 함유하는 세포증식 촉진용 조성물
WO2020055768A1 (en) 2018-09-10 2020-03-19 Cold Spring Harbor Laboratory Methods for treating pancreatitis
KR20200080179A (ko) * 2018-12-26 2020-07-06 아미코젠주식회사 아세틸콜린 수용체 저해 펩타이드 및 이의 용도
WO2021137932A1 (en) * 2019-11-04 2021-07-08 Faraday Pharmaceuticals, Inc. Use of iodide compounds for the treatment and prevention of chemotherapy-associated cachexia and cardiotoxicity
US12044516B2 (en) 2020-02-06 2024-07-23 Austin Star Detonator Company Integrated detonator sensors
KR102387136B1 (ko) * 2020-04-06 2022-04-14 재단법인대구경북과학기술원 탈모의 예방 또는 치료용 펩티드 및 이의 이용
WO2021245677A1 (en) * 2020-06-05 2021-12-09 Digestix Bioscience Inc. Compositions and methods for treating dysplastic and early-stage neoplastic conditions
CN111863118B (zh) * 2020-07-20 2023-09-05 湖南莱博赛医用机器人有限公司 基于tct制片进行tct和dna倍体分析的方法
EP4208186A1 (en) * 2020-09-04 2023-07-12 Dompe' Farmaceutici SpA Peptides endowed with angiogenic activity
CN112557347B (zh) * 2020-11-12 2023-10-24 渤海大学 一种黏液层中乳糜粒子迁移模型的制备及检测方法
KR20240036634A (ko) * 2021-07-23 2024-03-20 레터럴 아이피 피티와이 리미티드 란티오닌 합성효소 c-유사 단백질(lancl)에 결합할 수 있는 펩티드 조성물 및 그의 용도
US12492223B2 (en) 2021-07-23 2025-12-09 Lateral IP Pty Ltd Peptide compositions capable of binding lanthionine synthetase C-like protein (LanCl) and uses thereof
CN114606317B (zh) * 2022-03-22 2022-12-02 中山大学附属第一医院 一种预测胃癌淋巴结转移的菌群标志物及其应用
CN117106057B (zh) * 2022-08-19 2024-11-01 南京汉欣医药科技有限公司 一种高纯的人促肾上腺皮质激素或其类似物及其规模化制备方法
GB202215797D0 (en) 2022-10-25 2022-12-07 Solasta Bio Ltd Insect neuropeptide analogues
CN116983469B (zh) * 2023-08-03 2025-11-21 东华大学 一种水凝胶支架及其制备方法和应用
US12356995B2 (en) 2023-10-23 2025-07-15 Solasta Bio Limited Insect neuropeptides 9
US12302908B2 (en) 2023-10-23 2025-05-20 Solasta Bio Limited Insect neuropeptides 4
US12245588B1 (en) 2023-10-23 2025-03-11 Solasta Bio Limited Insect neuropeptides 2
US12245596B1 (en) * 2023-10-23 2025-03-11 Solasta Bio Limited Insect neuropeptides 8
US12279621B1 (en) 2023-10-23 2025-04-22 Solasta Bio Limited Insect neuropeptides 3
US12281143B1 (en) 2023-10-23 2025-04-22 Solasta Bio Limited Insect neuropeptides 1
CN118085024B (zh) * 2024-02-29 2025-12-26 南通大学 一种牦牛脾脏小分子多肽及其制备方法和应用
KR20260037706A (ko) 2024-09-09 2026-03-18 대한민국(농촌진흥청장) 리스테리아 모노사이토제네스 개체의 유전형 판별용 프라이머 세트 및 이의 용도

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
CH596313A5 (enExample) 1975-05-30 1978-03-15 Battelle Memorial Institute
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US4558006A (en) 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
EP0229108B1 (en) 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US6932968B1 (en) 1989-07-26 2005-08-23 Dade Behring Marburg Gmbh Erythropoietin (EPO) peptides and antibodies directed against these
DE3924746A1 (de) 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
WO1994005332A2 (en) 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5700909A (en) 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
US6271196B1 (en) 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
US6849602B1 (en) 1996-03-05 2005-02-01 The Regents Of The University Of California Compositions for alleviating neuropathic pain with prosaposin receptor agonists
US5952293A (en) 1996-03-08 1999-09-14 Receptron Receptor derived peptides involved in inhibition of receptor internalization in response to ligand binding
US6346390B1 (en) 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding
US5835382A (en) 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
US6437216B1 (en) 1997-11-13 2002-08-20 Interleukin Genetics Inc. Transgenic models of inflammatory disease
IL124015A0 (en) 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
TR200103785T2 (tr) 1999-04-13 2002-06-21 The Kenneth S. Warren Institute, Inc. Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi
WO2001083548A1 (en) 2000-04-28 2001-11-08 Effector Cell Institute Novel derivative of cell chemotactic factor
MXPA02011727A (es) * 2000-05-26 2003-10-24 Johnson & Johnson Peptidos neuroprotectores.
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
WO2002043572A2 (en) 2000-11-30 2002-06-06 Henry M. Jackson Foundation Erythropoietin and erythropoietin receptor expression in human cancer
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7241733B2 (en) 2002-06-28 2007-07-10 Centocor, Inc. Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
MXPA05000063A (es) * 2002-07-01 2005-04-08 Kenneth S Warren Inst Inc Citocinas recombinantes protectoras de tejido y acidos nucleicos que las codifican para la proteccion, restauracion y mejora de celulas, tejidos y organos respondedores.
US7037902B2 (en) 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
ZA200505423B (en) 2002-09-09 2008-08-27 Warren Pharmaceuticals Inc Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
WO2005025606A1 (en) 2003-09-09 2005-03-24 Warren Pharmaceuticals, Inc. Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
JP2004305006A (ja) 2003-04-01 2004-11-04 Japan Science & Technology Agency 人工調製肺サーファクタント
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
KR101163683B1 (ko) 2003-05-12 2012-07-10 아피맥스, 인크. 에리스로포이에틴 수용체에 결합하는 신규의 펩티드
JP2007512001A (ja) 2003-08-28 2007-05-17 バイオレクシス ファーマシューティカル コーポレイション Epoミメティックペプチドおよび融合タンパク質
CN1897959A (zh) 2003-09-29 2007-01-17 沃伦药品公司 用于治疗和预防脓毒病和粘连形成的组织保护细胞因子
US20050090551A1 (en) * 2003-10-27 2005-04-28 Board Of Trustees Of Southern Illinois University Therapeutic use of methionine for the treatment or prevention of mucositis
EP1718338B1 (en) 2004-02-02 2015-05-06 EnGeneIC Molecular Delivery Pty Ltd. Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
US20080227696A1 (en) * 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
AU2005222947B2 (en) * 2004-03-16 2010-12-23 Onconova Therapeutics Inc. Substituted phenoxy- and phenylthio- derivatives for treating proliferative disorders
WO2005099773A1 (en) 2004-04-05 2005-10-27 University Of Vermont And State Agricultural College Use of erythropoietin for treatment of cancer
WO2007010552A2 (en) * 2005-03-17 2007-01-25 Serum Institute Of India Limited N- terminal peg conjugate of erythropoietin
WO2007052154A2 (en) 2005-04-29 2007-05-10 University Of Medicine And Dentistry Of New Jersey Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US9345745B2 (en) 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
EP2377884A1 (en) 2005-05-10 2011-10-19 Neoloch Aps Neuritogenic peptides
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
WO2006127910A2 (en) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
EP1924276A4 (en) 2005-08-05 2009-07-22 Araim Pharmaceuticals Inc Antiperspirant peptides and their uses
EP2121740A2 (en) 2005-12-20 2009-11-25 Copenhagen University Neuritogenic and neuronal survival promoting peptides derived from the family of s-100 proteins
US8071544B2 (en) 2006-12-18 2011-12-06 Althea Technologies, Inc. Crystallized recombinant human growth factor formulations
WO2009094172A2 (en) 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage

Similar Documents

Publication Publication Date Title
JP2009149903A5 (enExample)
JP2016525888A5 (enExample)
JP2009091350A5 (enExample)
JP2009091351A5 (enExample)
JP2011102971A5 (enExample)
JP2018030858A5 (enExample)
JP2011518833A5 (enExample)
JP2010019854A5 (enExample)
JP2010501534A5 (enExample)
JP2011051867A5 (enExample)
JP2012111758A5 (enExample)
JP2011117499A5 (enExample)
JP2012511525A5 (enExample)
JP2013532130A5 (enExample)
JP2009139957A5 (enExample)
JP2011052077A5 (enExample)
JP2010049241A5 (enExample)
JP2011099964A5 (enExample)
JP2010070692A5 (enExample)
JP2010233885A5 (enExample)
JP2010037339A5 (enExample)
JP2009203373A5 (enExample)
JP2009249684A5 (enExample)
JP2011037885A5 (enExample)
JP2010246466A5 (enExample)